Cell Signaling Technology

Cell Signaling Technology, commonly known as CST, is a privately held biotechnology and life-science research company focused on tools for investigating cell signaling, protein regulation, and mechanisms of disease. Its product portfolio includes antibodies, enzyme-linked immunosorbent assay kits, chromatin immunoprecipitation kits, proteomic kits, and other reagents used by academic, pharmaceutical, biotechnology, and clinical-research laboratories. The company was established in 1999 by scientists associated with the Cell Signaling group at New England Biolabs. From its early base at the Cummings Center in Beverly, Massachusetts, CST developed a business centered on highly characterized antibodies and experimental products intended to help researchers detect signaling proteins, their phosphorylation states, and other post-translational modifications. This focus places the company within the research-tools sector rather than the therapeutic-drug or medical-device industries. CST’s offerings are used in methods such as Western blotting, immunohistochemistry, immunofluorescence, flow cytometry, immunoprecipitation, and ELISA. A notable part of its proposition is the development and validation of reagents for specific signaling proteins and modified protein forms, including phospho-specific antibodies. Its products support work in cancer biology, immunology, neuroscience, metabolism, developmental biology, and related fields. The company also develops application-oriented kits and assays intended to simplify pathway analysis and improve experimental consistency. In addition to commercial product development and manufacturing, CST maintains an internal research program. Its scientific activities include technology development for signaling analysis and mechanistic cell-biology research, with particular attention to cancer biology. The company has contributed to peer-reviewed scientific literature and has employed researchers involved in protein-signaling and proteomics research. CST also curates PhosphoSitePlus, an online bioinformatics resource containing information about post-translational modifications in human, mouse, and rat proteins. The database covers modifications including phosphorylation, acetylation, methylation, ubiquitylation, and glycosylation. PhosphoSitePlus is freely accessible and has received support from the U.S. National Institutes of Health, including support associated with the BD2K initiative. The company moved its U.S. headquarters to the former King’s Grant Inn site in Danvers in late 2005. After renovation, the facility received LEED certification from the U.S. Green Building Council in 2007. CST expanded its international presence in 2008 and 2009 by establishing subsidiary offices in China, Japan, and the Netherlands. In 2013, its production group moved into an ISO 9001-certified facility in Beverly, Massachusetts. The company has remained privately held and continues to operate as a specialist supplier of research reagents and signaling-analysis resources.

Cell Signaling Technology was founded in 1999 by scientists from the Cell Signaling group at New England Biolabs. The company was created to develop and supply research products for studying intracellular signaling pathways and the molecular mechanisms that influence human health. Its early operations were based at the Cummings Center in Beverly, Massachusetts. CST’s business developed around antibodies and related analytical products, with particular emphasis on reagents capable of detecting signaling proteins and specific post-translational modifications. Phosphorylation is especially important in signal-transduction research because it can alter protein activity, localization, and interactions. The company therefore built a portfolio that included conventional and phospho-specific antibodies, ELISA products, chromatin immunoprecipitation kits, proteomic kits, and other research reagents. These products are used in laboratory techniques including Western blotting, immunohistochemistry, immunofluorescence, flow cytometry, immunoprecipitation, and ELISA. The company also pursued research beyond routine product manufacture. CST developed technologies for signaling analysis and conducted mechanistic cell-biology research, particularly in cancer research. Its scientific work has been represented in peer-reviewed publications. A related part of its scientific contribution is PhosphoSitePlus, a web-based resource that catalogs post-translational modifications in human, mouse, and rat proteins. The resource includes phosphorylation as well as acetylation, methylation, ubiquitylation, glycosylation, and other modification types. It is freely available to researchers and has received partial support through grants from the U.S. National Institutes of Health, including the BD2K initiative. In late 2005, CST moved its U.S. headquarters from the Cummings Center to the former King’s Grant Inn property in Danvers, Massachusetts. The site underwent substantial renovation and received LEED certification from the U.S. Green Building Council in 2007. The move gave the company a larger purpose-built base for its corporate, research, and operational activities. CST expanded internationally during 2008 and 2009, establishing subsidiary offices in China, Japan, and the Netherlands. These offices supported the company’s growing global customer base in academic research, biotechnology, and pharmaceutical science. In 2013, CST moved its production group into an ISO 9001-certified facility in Beverly, Massachusetts, marking an operational development in its manufacturing and quality infrastructure. The company has remained privately held. Its identity has continued to be tied to specialized research reagents, antibody validation, pathway analysis, and scientific support rather than consumer products or therapeutic medicines. Publicly available reference material also records CST’s inclusion in the Boston Globe’s Top 100 Places to Work survey from 2009 through 2013. Overall, the company’s history reflects the growth of a Massachusetts life-science supplier from a New England Biolabs-associated start-up into an international provider of signaling-research products and data resources.

1. 2013Production group moved to an ISO 9001-certified facility

   CST relocated its production group into an ISO 9001-certified facility in Beverly, Massachusetts.

   Source
2. 2009Japanese and Dutch subsidiary offices established

   The company continued its international expansion with subsidiary offices in Japan and the Netherlands.

   Source
3. 2008Chinese subsidiary office established

   CST expanded its overseas operations by establishing a subsidiary office in China.

   Source
4. 2007Danvers facility received LEED certification

   Following renovation, the company’s Danvers headquarters was certified under the U.S. Green Building Council’s LEED program.

   Source
5. 2005Headquarters moved to Danvers

   CST moved its U.S. headquarters from the Cummings Center in Beverly to the former King’s Grant Inn site in Danvers, Massachusetts.

   Source
6. 1999Company founded

   Cell Signaling Technology was founded by scientists from the Cell Signaling group at New England Biolabs.

   Source

A specialist, quality-focused supplier of validated antibodies, pathway assays, and related research tools for cell signaling, cancer biology, and mechanistic life-science research.

• Research antibodiesAntibodies

  CST develops antibodies for detecting proteins involved in signaling pathways and other cellular processes. The products are used across applications such as Western blotting, immunohistochemistry, immunofluorescence, flow cytometry, and immunoprecipitation. The portfolio includes antibodies directed at signaling proteins, disease-related targets, and modified forms of proteins.

• Phospho-specific antibodiesAntibodies

  These antibodies are designed to recognize particular phosphorylation states of proteins. They support analysis of pathway activation and regulation, allowing researchers to examine changes in signaling under different experimental or disease conditions. They are central to CST’s positioning in signal-transduction research.

• PathScan ELISA kitsELISA kits

  PathScan ELISA kits provide assay formats for measuring selected signaling proteins or phosphorylation events. By packaging detection reagents and protocol components into standardized kits, they are intended to make pathway-focused analysis more accessible and reproducible than assembling every assay component independently.

• Chromatin immunoprecipitation kitsMolecular biology kits

  CST’s chromatin immunoprecipitation products support studies of protein–DNA interactions and transcriptional regulation. Such kits are used to investigate whether selected proteins or histone modifications are associated with particular genomic regions, linking signaling activity to gene-regulatory outcomes.

• Proteomic kits and reagentsProteomics

  Proteomic products from CST are intended for analyzing proteins and their modifications in complex biological samples. They complement the company’s antibody and pathway-assay businesses and support research into protein abundance, signaling networks, and post-translational regulation.

• PhosphoSitePlusBioinformatics resource

  PhosphoSitePlus is a freely accessible database curated by CST that records post-translational modifications in human, mouse, and rat proteins. Its coverage includes phosphorylation, acetylation, methylation, ubiquitylation, glycosylation, and other modification types. It is used as a reference resource for signaling and proteomics research.

• 2009Cell Signaling Technology expands operations in Japan and the Netherlands

  The company established subsidiary offices in Japan and the Netherlands, extending its international support and commercial infrastructure.

  Other
  Source
• 2009Cell Signaling Technology recognized among Boston’s Top 100 Places to Work

  CST was included in the Boston Globe’s Top 100 Places to Work survey, an appearance that was repeated in subsequent years through 2013.

  Other
  Source
• 2008Cell Signaling Technology expands international operations

  CST established a subsidiary office in China as part of an expansion of its overseas operations.

  Other
  Source

1. Cell Signaling Technology
2. Cell Signaling Technology official website